We are thrilled to announce that Humaneva Inc. has entered into a significant investment agreement with Viking Global Investors, a global investment firm based in the United States (“Viking”). Under this agreement, Viking acquired a minority stake in Humaneva Inc., a spin-off of NEUCA S.A, for $50M with a one-year option to invest an additional $50M. “The clinical trials market is undergoing rapid transformation, driven by global consolidation and innovative business models. Partnering with Viking is a strategic milestone for us. Viking’s unique blend of hedge fund and private equity expertise, coupled with their long-term, value-building perspective, aligns perfectly with Humaneva's vision,” said Tomek Dabrowski, CEO of Humaneva Inc. “The United States accounts for nearly 80% of all R&D expenditures in the clinical trials market. Strengthening our presence, especially in the US, will significantly expand our scale and capabilities in the coming years.” READ MORE: https://lnkd.in/dxD72hYM
About us
Humaneva stands at the intersection of Patient care and scientific innovation, offering reliable clinical research data that empowers the medical community. ABOUT HUMANEVA Humaneva Group emerged from our unwavering commitment to integrating clinical research with technological innovation and data-driven approaches. The Group consists of three interrelated companies, each excelling in its specialized domain within the field of clinical research. Individually outstanding, together they form a perfectly integrated alliance, creating a seamless data stream between Patients, Investigators, Research Centres, and data standards. OUR SUPERIOR CLIENT VALUE: direct access to Patients & reliable data on time. Our unique value proposition is based on three operational segments: 1. Our SMO (Pratia) organization's operations and expertise favor our ability to find the right patient at the right time and place; 2. Our in-house, state-of-the-art TECH (Hyggio) permeates and harmonizes operations at both the CRO and SMO levels, enabling scalable, comprehensive, cost-effective, fast and high-quality data analysis; 3. Managing clinical projects within the CRO (Kapadi) provides natural vertical integration synergies and superior savings of time and money for the sponsor. By prioritizing patient care, leveraging technology, and championing data excellence in oncology and other therapeutic areas, Humaneva Group is forging a path to groundbreaking discoveries and the betterment of Patient health worldwide. Join Humaneva Group in redefining the future of clinical research, where every Patient's story contributes to a larger narrative of hope and healing.
- Website
-
www.humaneva.com
External link for Humaneva Group
- Industry
- Research Services
- Company size
- 1,001-5,000 employees
- Headquarters
- Raleigh , North Carolina
- Type
- Privately Held